Biologics

Description : Mycelium protein powder (mycoprotein) is a whole-food fungal protein and prebiotic dietary fibre ingredient produced via aerobic submerged or solid-state fermentation of filamentous fungal mycelia (such as Fusarium venenatum or edible macromycetes). Fungal Biomass Derivative combines complete protein containing all nine essential amino acids with a native structural beta-glucan and chitin-glucan fibre network. As international food processing firms and functional food brands search for sustainable protein solutions that deliver natural fibrous bite and chew without excessive synthetic texturizers, demand for fermentation-derived mycelium biomass has surged. Formulation teams face critical processing challenges, including fungal RNA management, uniform rehydration kinetics, continuous batch consistency, and particle dispersion during wet extrusion. Sourcing through our certified commercial fermentation platform guarantees an advanced fungal ingredient providing ≥ 50.0% protein and ≥ 20.0% dietary fibre on a dry-weight basis. Our industrial bioprocessing utilizes continuous stirred-tank reactors (CSTR) or solid-state bioreactors, followed by rapid thermal RNA-reduction treatment, vacuum centrifugation harvesting, mild drying, and precision milling. Global meat-alternative producers, dietary supplement developers, and industrial food formulators partner with us as their trusted mycelium protein supplier to maintain reliable raw material pipelines and eliminate cross-border logistical disruptions. Every production batch is backed by complete analytical documentation aligned with international food regulations, ISO 22000 standards, EFSA Novel Food evaluations, and cGMP manufacturing codes. As globally established mycelium protein powder supplier with ≥ 50% purity, we ensure dependable supply, consistent quality, and complete regulatory documentation, including Mycelium Protein Powder CoA and Mycelium Protein Powder TDS across all grades.

Description : Yeast protein powder (CAS No: 8013-01-2) is a non-animal, complete single-cell protein produced via precision aerobic submerged fermentation of Saccharomyces cerevisiae, supplying an intact essential amino acid profile with high branched-chain amino acid (BCAA) density. As global food technology, clinical nutrition, and sports formulation sectors move away from carbon-intensive dairy proteins and allergen-prone soy isolates, commercial formulators require sustainable, allergen-free macromolecular ingredients. Sourcing teams and plant managers frequently confront taste-masking barriers, off-flavour formation, variable dispersibility, and nucleic acid accumulation when evaluating single-cell proteins. Sourcing through our certified global fermentation platform provides an advanced yeast protein powder delivering ≥ 70.0% protein content on a dry-weight basis, complete with low residual ribonucleic acid levels (< 2.0%) achieved via enzymatic degradation and automated heat-shock processing. Our industrial-scale processing utilises computer-controlled fed-batch bio-reactors, mechanical cell-wall disruption via high-pressure homogenisation, multi-stage centrifugal clarification, and gentle low-temperature spray drying. Sourcing teams and contract manufacturers partner with us as their certified global yeast protein powder supplier to bypass agricultural harvest cycles, secure consistent lot-to-lot emulsification, and ensure protein solubility across neutral and acidic beverage formulations. Every production batch is backed by full analytical dossiers verifying non-GMO status, allergen-free certification, ISO 22000 food safety management compliance, EU Novel Food status, and cGMP adherence. As globally established yeast protein powder supplier with ≥ 70% purity, we ensure dependable supply, consistent quality, and complete regulatory documentation, including yeast protein powder CoA. Scimplify lifescience supports the complete journey from research and process development to pilot-scale production and full commercial contract manufacturing, supplying chemical building blocks across life sciences and crop sciences with all manufacturing and decentralised supply operations strictly aligned with applicable FDA, USP, and global regulatory compliance requirements.

Description : Lanreotide acetate - (CAS No: 108736-35-2 (Free Base) | 127984-74-1 (Acetate Salt) - is a synthetic cyclic octapeptide analog of native somatostatin, engineered with a stable intramolecular disulfide bridge between Cys2 and Cys7 and incorporating non-natural D-beta-naphthylalanine at position 1. Lanreotida selectively targets human somatostatin receptors (predominantly SSTR2 and SSTR5), repressing the hypersecretion of growth hormone (GH), insulin-like growth factor 1 (IGF-1), and gastroenteropancreatic peptides. Across the international oncology and endocrinology sectors, procurement requirements have transitioned decisively from daily subcutaneous injections to monthly, pre-filled, polymer-free autogel depot formulations. These advanced depot systems rely directly on the intrinsic capacity of lanreotidum to spontaneously self-assemble into well-ordered, monodisperse cylindrical nanotubes in pure aqueous media without requiring exogenous PLGA carriers. Peptide synthesis facilities face substantial manufacturing and quality challenges during this process, particularly maintaining correct disulphide connectivity, preventing anti-parallel or parallel dimerisation, and stripping trace trifluoroacetic acid (TA) down to sub-percentage thresholds. Global finished dose formulators, hospital tenders, and contract development organisations resolve these production barriers by securing bulk active substance through an established commercial Lanreotide Acetate API supplier delivering > 99.0% purity by reverse-phase HPLC. Partnering with a dedicated manufacturer guarantees controlled counter-ion ratios (9.0% - 13.0% acetic acid content), minimal deletion sequences, low residual organic volatiles, and verified endotoxin thresholds (< 0.33 EU/mg), securing unhindered reconstitution and predictable depot gel viscosities. Every production lot is supported by complete analytical documentation aligned with European Pharmacopoeia (Ph. Eur.) monographs, EU REACH protocols, cGMP manufacturing standards, and WHO-GMP guidelines. We are an established Lanreotide API supplier with ≥ 99% purity globally for API formulators, providing comprehensive analytical (HPLC/NMR/MS) and supporting Lanreotide COA/TDS/ Lanreotide Acetate SDS. Beyond supply, we support partners with region-specific compliances, GMP quality assurance, and regulatory documentation through global supply chain capabilities and logistics coordination.

Description : We supply high-purity Serratiopeptidase (CAS No: 37312-62-2) to facilitate commercial anti-inflammatory API formulation, proteolytic enzyme processing, enteric tablet manufacturing, and CDMO bioprocessing across international healthcare markets. Known across global biopharma supply chains as Serratia peptidase E-15, this extracellular zinc metalloproteinase hydrolyses bradykinin, histamine, and fibrin networks to alleviate localised swelling, reduce pain, and enhance antibiotic tissue penetration. Produced through aerobic fermentation of non-pathogenic Serratia E-15 or recombinant expression systems, followed by tangential flow microfiltration, ultrafiltration, and low-temperature Iyophilisation or spray drying, the refined enzyme achieves a catalytic activity profile of > 2,000 U/mg with strictly controlled bioburden levels. Global pharmaceutical manufacturers and nutritional supplement formulators incorporate this proteolytic enzyme into enteric-coated tablets, delayed-release capsules, and topical anti-oedema gels targeting post-operative swelling, sinusitis, and joint inflammation. Formulators and biopharmaceutical processors partner with us as their certified global serrapeptase supplier to maintain continuous active raw material reserves and eliminate cross-border bioprocess supply chain bottlenecks. Choosing us as your trusted serralysin supplier guarantees an advanced enzyme ingredient that provides uniform batch-to-batch activity retention, excellent gastric-resistance compatibility during film coating, and long-term shelf-life stability. Engineering and quality assurance teams can verify our strict material metrics by downloading our batch-specific Serratiopeptidase COA and Serratiopeptidase TDS documentation, which details precise enzyme activity units, heavy metal thresholds (≤ 10 ppm), residual moisture, and microbiological purity limits. We are an established Serratiopeptidase API supplier with ≥ 99% purity globally for semi-finished formulators, providing comprehensive analytical (HPLC/NMR/MS) and supporting Serratiopeptidase SDS.

Description : We supply a high-purity Rifampicin (CAS No: 13292-46-1) to promote commercial anti-tubercular API formulation, broad-spectrum antimicrobial processing, and CDMO biomanufacturing across international healthcare markets. Known across global biopharma supply chains as rifampin, rifamycin SV derivative, this semisynthetic ansamycin antibiotic features a naphthalene ring spanned by an aliphatic bridge, functioning by inhibiting bacterial DNA-dependent RNA polymerase. Produced through aerobic submerged fermentation of Amycolatopsis mediterrane to isolate rifamycin B, followed by chemical transformation to 3-formylrifamycin SV and condensation with 1-amino-4-methylpiperazine, the refined active ingredient achieves an API assay of ≥ 99% with strictly controlled degradation products such as rifampicin quinone and 3-formylrifamycin SV. Global pharmaceutical manufacturers and public health agencies incorporate this active ingredient into fixed-dose combination (FDC) oral tablets, soft gelatin capsules, and sterile intravenous vials targeting Mycobacterium tuberculosis, Mycobacterium leprae, and severe methicillin-resistant staphylococcal infections. Formulators and biopharmaceutical processors partner with us as their certified global rifampin supplier to maintain continuous active ingredient reserves and eliminate cross-border bioprocess supply chain bottlenecks. Choosing us as your trusted rifampicin supplier guarantees an advanced active pharmaceutical ingredient that provides uniform batch-to-batch crystalline morphology, rapid dissolution, low residual solvent baselines, and long-term shelf-life stability during solid dose and parenteral manufacturing. Incoming QC teams can verify our strict material metrics by downloading our batch-specific Rifampicin COA and Rifampicin TDS documentation, which details precise HPLC purity profiles, individual related substance limits (≤ 1.0%), heavy metal thresholds (≤ 10 ppm), and residual solvent profiles. We are an established rifampicin API supplier with >

Description : Operating as a high-potency lipoglycopeptide antibacterial complex, teicoplanin active substance (CAS No: 61036-62-2) is synthesised via large-scale aerobic submerged fermentation of the actinobacterium Actinoplanes techomyceticus. This advanced active pharmaceutical ingredient comprises five closely related core components (A2-1 through A2-5) alongside a congener core (A3-1), each possessing a central heptapeptide backbone decorated with specific fatty-acid acyl chains. The unique lipophilic side chains anchored to its aglycone core enhance membrane binding, extending its systemic elimination half-life and conferring superior tissue penetration over traditional non-lipophilic glycopeptides. Our commercial manufacturing facility utilises 60KL high-capacity industrial fermenters integrated with automated multi-stage column chromatography and cGMP crystallisation lines to isolate the drug substance at an API assay of ≥ 99%. Global pharmaceutical formulators and hospital supply contractors source this lipoglycopeptide active ingredient to manufacture critical parenteral anti-infectives targeting methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus faecalis, and severe Gram-positive hospital-acquired infections. Biopharmaceutical procurement managers, generic drug manufacturers, and regional health authority suppliers choose our certified global teicoplanin active substance to prevent batch-to-batch ratio shifts among the five A2 sub-components, ensuring compliance with European Pharmacopoeia (Ph. Eur.) and international monograph standards. Quality assurance and regulatory compliance managers can verify teicoplanin batch-specific parameters, such as total A2 component ratio (≥ 80.0%), residual solvent thresholds, and endotoxin levels (< 0.05 EU/mg). We are an established Teicoplanin API supplier with ≥ 99% purity globally for semi-finished formulators, providing comprehensive analytical (HPLC/NMR/MS) and supporting Teicoplanin COA/TDS/SDS. Beyond supply, we support partners with region-specific compliances, GMP quality assurance, and regulatory documentation through global supply chain capabilities and logistics coordination.

Description : We offer high-purity Vancomycin (CAS No: 1404-90-6) to power commercial anti-infective API formulation, hospital-grade parenteral drug compounding, and CDMO bioprocessing across international healthcare markets. Known across global biopharma supply chains as Glycopeptide antibiotic B-55884, this complex branched tricyclic glycopeptide acts by binding with high affinity to the D-alanyl-D-alanine terminus of cell wall peptidoglycan precursors, preventing bacterial cell wall cross-linking and osmotic stabilization. Produced through aerobic submerged fermentation of Amycolatopsis orientalis followed by high-pressure cell homogenization, multi-column preparative ion-exchange chromatography, and cGMP crystallisation, the refined active ingredient achieves an API assay of ≥ 99% with strictly controlled degradation products such as vancocin crystalline monohydrochloride and aglucovancomycin. Global pharmaceutical manufacturers and API formulation specialists are expanding their anti-infective capacity to address methicillin-resistant Staphylococcus aureus (MRSA) and enterococcal threats, selecting our strictly refined material to eliminate related fermentation impurities and prevent reconstitution turbidity in sterile injectable vials. Formulators and contract development manufacturing organisations partner with us as their certified global vancomycin hydrochloride supplier to secure continuous active ingredient reserves and bypass cross-border bioprocess supply chain bottlenecks. Choosing us as your trusted vancocin supplier guarantees an advanced active pharmaceutical ingredient that provides uniform batch-to-batch lyophilisate cake structure, rapid aqueous dissolution kinetics, low endotoxin baselines (< 0.25 EU/mg), and long-term shelf-life stability during parenteral and oral solution processing. Engineering and quality assurance teams can verify our strict material metrics by downloading our batch-specific Vancomycin COA & Vancomycin TDS documentation, which details precise HPLC purity profiles, individual related substance limits ( ≤ 1.0%), heavy metal thresholds (≤ 10 ppm), and residual solvent profiles. We are an established Vancomycin API supplier with ≥ 99% purity globally for formulators, providing comprehensive analytical (HPLC/NMR/MS) and supporting Vancomycin COA/SDS.

Description : Fusidic acid is a specialized steroidal antibacterial agent isolated via fungal fermentation of Fusidium coccineum, functioning by inhibiting bacterial protein synthesis through preventing the turnover of elongation factor G (EF-G) from the ribosome. We supply high-purity fusidate active substance (CAS 6990-06-3) to support commercial API formulation, dermatological drug compounding, ophthalmic therapeutics, and CDMO bioprocessing across international markets. Known in global biopharma trade channels as fusidic acid, this tetracyclic steroidal antibiotic possesses a unique cyclopentanoperhydrophenanthrene skeleton that provides selective bacteriostatic activity primarily against Gram-positive pathogens, including Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA). Produced through submerged fungal fermentation of Fusidium coccineum followed by multi-stage downstream extraction, membrane filtration, and cGMP crystallisation, the refined active pharmaceutical ingredient achieves ramycin high purity (≥ 98.0%). Global pharmaceutical companies, generic drug formulators, and contract manufacturers incorporate this active ingredient to produce topical ointments, creams, ophthalmic drops, and oral tablet formulations. Formulators and biopharmaceutical processors partner with us as their certified global fusidic acid supplier to maintain continuous raw material reserves and bypass international bioprocess bottlenecks. Selecting us as your trusted fucidin supplier guarantees a high-grade active pharmaceutical ingredient providing low residual solvent levels, uniform crystalline micronisation, and long-term stability during cream base compounding. Technical and quality assurance teams can verify our material metrics by downloading our batch-specific Fusidic Acid COA & TDS documentation, detailing precise HPLC purity, specific optical rotation, heavy metal thresholds (≤10 ppm), and microbiological purity limits. Accessing our official sodium fusidate sds guarantees full compliance with global standards, including European REACH registration, (Ph. Eur.), IP, BP, cGMP standards, and ISO 9001 quality management rules. Partner with us as your preferred fusidic acid supplier to lock in commercial API contracts and scale your anti-infective drug manufacturing lines.

Description : Cyclosporin is a lipophilic cyclic undecapeptide produced via fungal fermentation of Tolypocladium inflatum, functioning as a potent calcineurin-inhibiting immunosuppressive agent that selectively suppresses T-cell-mediated immune responses. We supply high-purity cyclosporin A (CAS No: 59865-13-3) to support commercial API formulation, organ transplant therapy, ophthalmology, and CDMO bioprocessing across international markets. Known in global biopharma supply chains as cyclosporin A, this 11-amino acid cyclic peptide contains unique non-proteinogenic amino acids (including (2S, 3R, 4E)-2-amino-3-hydroxy-4-methyloct-4-enoic acid or MeBmt), which enable high-affinity binding to intracellular cyclophilin-18 (Cyp-18). Produced through submerged fungal fermentation followed by solvent extraction, multi-column chromatography, and cGMP crystallisation, the refined active pharmaceutical ingredient achieves high chemical purity (≥ 98.5%). Global pharmaceutical companies, generic drug formulators, and contract manufacturers incorporate this active ingredient to formulate oral microemulsions, soft gelatin capsules, IV infusions, and ophthalmic emulsions targeting organ graft rejection, rheumatoid arthritis, psoriasis, and dry eye disease. Formulators and biopharmaceutical processors partner with us as their certified global ciclosporin supplier to maintain continuous raw material reserves and bypass international bioprocess bottlenecks. Selecting us as your trusted cyclosporine supplier guarantees a high-grade active pharmaceutical ingredient providing low residual solvent levels, uniform crystalline micronisation, and long-term stability during microemulsion self-emulsifying system (SEDDS) compounding. Technical and quality assurance teams can verify our material metrics by downloading our batch-specific Cyclosporin COA and Cyclosporin TDS documentation, detailing precise HPLC Cyclosporin purity, specific optical rotation, heavy metal thresholds (≤ 10 ppm), and microbiological purity limits. Accessing our official Cyclosporin COA and Cyclosporin TDS technical packages ensures full compliance with global standards, including European REACH registration, European Pharmacopoeia (Ph. Eur.), cGMP standards, and ISO 9001 quality management rules. Partner with us as your preferred cyclosporine supplier to lock in commercial API contracts and scale your immunosuppressive drug manufacturing lines worldwide.

Description : Mupirocin is a natural crotonic acid derivative produced via fermentation of the bacterium Pseudomonas fluorescens, acting as a potent topical antibacterial agent that reversibly inhibits bacterial isoleucyl-transfer RNA synthetase. We supply high-purity pseudomonic acid A (CAS No: 12650-69-0) to support commercial API formulation, dermatological drug compounding, CDMO bioprocessing, and speciality pharmaceutical manufacturing across international markets. Known in global biopharma trade channels as mupirocin, pseudomonic acid, or pseudomonic acid A, this bioactive fermentation metabolite contains a unique tetrahydropyran ring linked to a 9-hydroxynonanoic acid tail, enabling target-specific binding to bacterial isoleucyl-tRNA synthetase without cross-resistance to other antibiotic classes. Produced through large-scale aerobic submerged fermentation followed by advanced membrane filtration, solvent extraction, and cGMP crystallisation, the refined active ingredient achieves high chemical purity (> 98.0%). Global pharmaceutical companies, generic drug formulators, and contract manufacturers incorporate this active ingredient to formulate topical ointments, creams, and nasal sprays targeting methicillin-resistant Staphylococcus aureus (MRSA) and impetigo. Formulators and biopharmaceutical processors partner with us as their certified global pseudomonic acid A supplier to maintain continuous raw material reserves and bypass international bioprocess bottlenecks. Selecting us as your trusted pseudomonic acid supplier guarantees a high-grade active pharmaceutical ingredient providing low residual solvent levels, uniform crystalline micronisation, and long-term stability during topical base formulation.Technical and quality assurance teams can verify our material metrics by downloading our batch-specific Mupirocin COA detailing precise HPLC purity, specific optical rotation, heavy metal thresholds (≤ 10 ppm), and microbiological purity limits. Accessing our official Mupirocin TDS technical package ensures full compliance with global standards, including European REACH registration, European Pharmacopoeia (Ph. Eur.), cGMP standards, and ISO 9001 quality management rules. Partner with us as your preferred Mupirocin supplier to lock in commercial API contracts and scale your topical drug manufacturing lines.

Description : Tacrolimus (CAS No: 104987-11-3) continues to serve as a cornerstone calcineurin inhibitor within the global immunosuppressant market, where its high-potency macrolide structure is increasingly vital for preventing allograft rejection in renal, hepatic, and cardiac transplantation. The pharmaceutical landscape is witnessing a strategic shift towards advanced drug delivery systems, such as once-daily extended-release formulations and topical ointments, to improve patient adherence and mitigate the systemic side effects typically associated with long-term transplant care. Market intelligence indicates that as generic penetration accelerates following the loss of exclusivity for major branded products, leading CDMOs and API manufacturers are differentiating themselves through high-purity crystalline forms and robust pharmacovigilance programmes to meet the rigorous regulatory standards of the North American and European healthcare sectors. We are an established Tacrolimus API supplier with >= 99% purity globally for semi-finished formulators, providing comprehensive analytical (HPLC/NMR/MS) and supporting Tacrolimus COA/TDS/SDS region-specific regulatory support, reliable lead times, and worldwide supply chain capabilities.

Description : Orlistat is a saturated derivative of lipstatin isolated from the actinobacterium Streptomyces toxytricini, functioning as a potent, reversible pancreatic and gastric lipase inhibitor that reduces dietary fat absorption in the gastrointestinal tract. We supply high-purity tetrahydrolipstatin (CAS No: 96827-07-5) to support commercial API formulation, metabolic health therapeutics, obesity management, and CDMO bioprocessing across international markets. Known in global biopharma trade channels as THL, this beta-lactone derivative covalent-binds to the active serine site of gastric and pancreatic lipases, preventing the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. Produced through large-scale fermentation of Streptomyces toxytricini to yield lipstatin, followed by catalytic hydrogenation, downstream extraction, and cGMP crystallisation, the refined api achieves > 98.0% Orlistat high purity. Global pharmaceutical companies, generic drug formulators, and contract manufacturers incorporate this active ingredient to produce prescription oral capsules (120 mg) and over-the-counter weight-loss formulations (60 mg). Formulators and biopharmaceutical processors partner with us as their certified global tetrahydrolipstatin supplier to maintain continuous raw material reserves and bypass international bioprocess bottlenecks. Selecting us as your trusted orlistat supplier guarantees a high-grade active pharmaceutical ingredient providing low residual solvent levels, uniform particle size distributions, and long-term stability during oral capsule compounding. Technical and quality assurance teams can verify our material metrics by downloading our batch-specific Orlistat COA, Sds, detailing precise HPLC purity, specific optical rotation, heavy metal thresholds ( ≤ 10 ppm), and microbiological purity limits. Accessing our official Orlistat TDS ensures full compliance with global standards, including European REACH registration, European Pharmacopoeia (Ph. Eur.), cGMP standards, and ISO 9001 quality management rules. Partner with us as your preferred Orlistat supplier to lock in commercial API contracts and scale your metabolic health drug manufacturing lines.